X. Huang

发表

Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study

P. Jänne, D. Planchard, S. Kim, 2021, ESMO open.

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours

J. Heymach, L. Tye, H. Lenz, 2015, British Journal of Cancer.

PL3.5 Efficacy and safety of selinexor in recurrent glioblastoma

P. Wen, M. J. van den Bent, A. Lassman, 2019, Neuro-Oncology.

1331PDetection of EGFR T790M in Asia-Pacific patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Circulating tumour (ct) DNA analysis across 3 platforms

S. Patel, Y. Wu, C. Zhou, 2017 .

PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers

A. Drilon, M. Burkard, Melissa L. Johnson, 2019, Journal of Thoracic Oncology.

Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors.

J. Heymach, L. Tye, H. Lenz, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α

R. Figlin, R. Motzer, M. Michaelson, 2012, British Journal of Cancer.

Genetic analysis of proteasome-related pathways in patients with advanced gastric adenocarcinomas (AGA) treated on a phase II study with PS-341 (bortezomib) with or without irinotecan.

S. Wadler, J. Wright, A. Ocean, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC).

R. Greil, J. Bergh, K. Kern, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC).

K. Kern, G. Romieu, J. Crown, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumors: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

G. Demetri, R. Doebele, R. Dziadziuszko, 2019, Annals of Oncology.

O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001)

A. Drilon, G. Demetri, R. Doebele, 2020 .

Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis

Ying Cheng, M. Ahn, T. Mok, 2020 .

Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC).

R. Figlin, R. Motzer, M. Michaelson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

56P Anti-PD1 antibody toripalimab, lenvatinib and gemox chemotherapy as first-line treatment of advanced and unresectable intrahepatic cholangiocarcinoma: A phase II clinical trial

Yingyong Hou, S. Qiu, Yang Xu, 2020 .

An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer

M. Collier, K. Kern, K. Miller, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status.

C. Antonescu, J. Fletcher, G. Demetri, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.

A. Guerrero-Zotano, M. Koehler, M. Margelí, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Construction of microsatellite-based linkage maps and identification of size-related quantitative trait loci for Zhikong scallop (Chlamys farreri).

A. Zhan, M. Wang, Xiaoli Hu, 2009, Animal genetics.

OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer

A. Drilon, B. Tuch, T. Mok, 2018, Journal of Thoracic Oncology.

Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.

R. Figlin, R. Motzer, M. Michaelson, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment

R. Finn, J. Crown, I. Láng, 2016, Current medical research and opinion.

Circulating protein biomarkers of sunitinib (SU) and interferon-α (IFN-α) efficacy in treatment (Tx)-naive patients (pts) with metastatic renal cell carcinoma (mRCC).

R. Figlin, R. Motzer, M. Michaelson, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FP16.03 Early Circulating-Tumor DNA EGFR Mutation Clearance in Plasma as a Predictor of Clinical Outcomes in The AURA3 Trial

S. Ramalingam, Y. Wu, A. Delmonte, 2021, Journal of Thoracic Oncology.

Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

A. Drilon, R. Doebele, F. Barlesi, 2019, Annals of Oncology.

Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.

A. Drilon, G. Demetri, M. Ahn, 2020 .

Selpercatinib (LOXO-292) in patients with RET-Fusion+ non small-cell lung cancer (NSCLC)

A. Drilon, J. Wolf, B. Besse, 2020, Pneumologie.

Neuroendocrine tumors and CUP

A. Carrato, M. Kudo, R. Salazar, 2012 .